BNP Paribas Financial Markets’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-18,556
| Closed | -$2.38M | – | 5573 |
|
|
2025
Q2 | $2.38M | Buy |
18,556
+13,524
| +269% | +$1.4M | ﹤0.01% | 2360 |
|
|
2025
Q1 | $445K | Sell |
5,032
-7,453
| -60% | -$727K | ﹤0.01% | 3256 |
|
|
2024
Q4 | $1.09M | Sell |
12,485
-9,526
| -43% | -$873K | ﹤0.01% | 2766 |
|
|
2024
Q3 | $2.04M | Buy |
22,011
+3,326
| +18% | +$330K | ﹤0.01% | 2030 |
|
|
2024
Q2 | $2.01M | Sell |
18,685
-41,352
| -69% | -$4.14M | ﹤0.01% | 1917 |
|
|
2024
Q1 | $5.7M | Sell |
60,037
-91,656
| -60% | -$7.86M | 0.01% | 1375 |
|
|
2023
Q4 | $14M | Buy |
151,693
+71,812
| +90% | +$4.65M | 0.02% | 872 |
|
|
2023
Q3 | $4.01M | Buy |
79,881
+44,369
| +125% | +$2.37M | 0.01% | 1425 |
|
|
2023
Q2 | $2.24M | Sell |
35,512
-32,756
| -48% | -$1.78M | ﹤0.01% | 1687 |
|
|
2023
Q1 | $3.07M | Buy |
68,268
+1,373
| +2% | +$61.9K | ﹤0.01% | 1544 |
|
|
2022
Q4 | $2.93M | Sell |
66,895
-1,034
| -2% | -$49.6K | ﹤0.01% | 1563 |
|
|
2022
Q3 | $4.48M | Buy |
67,929
+38,261
| +129% | +$2.46M | 0.01% | 1424 |
|
|
2022
Q2 | $1.5M | Buy |
29,668
+21,200
| +250% | +$1.24M | ﹤0.01% | 1936 |
|
|
2022
Q1 | $541K | Sell |
8,468
-3,893
| -31% | -$279K | ﹤0.01% | 2703 |
|
|
2021
Q4 | $1.32M | Buy |
12,361
+1,846
| +18% | +$193K | ﹤0.01% | 2388 |
|
|
2021
Q3 | $1.08M | Buy |
10,515
+4,345
| +70% | +$405K | ﹤0.01% | 2320 |
|
|
2021
Q2 | $543K | Sell |
6,170
-1,336
| -18% | -$122K | ﹤0.01% | 2483 |
|
|
2021
Q1 | $730K | Sell |
7,506
-15,462
| -67% | -$1.54M | ﹤0.01% | 2337 |
|
|
2020
Q4 | $2.58M | Buy |
22,968
+10,070
| +78% | +$1.06M | ﹤0.01% | 1492 |
|
|
2020
Q3 | $1.2M | Sell |
12,898
-31,848
| -71% | -$2.45M | ﹤0.01% | 1734 |
|
|
2020
Q2 | $3.49M | Sell |
44,746
-20,468
| -31% | -$1.38M | 0.01% | 1236 |
|
|
2020
Q1 | $3.81M | Sell |
65,214
-20,523
| -24% | -$1.32M | 0.01% | 1112 |
|
|
2019
Q4 | $6.87M | Buy |
85,737
+76,753
| +854% | +$5.75M | 0.01% | 1032 |
|
|
2019
Q3 | $660K | Buy |
8,984
+2,828
| +46% | +$244K | ﹤0.01% | 2052 |
|
|
2019
Q2 | $581K | Sell |
6,156
-3,432
| -36% | -$283K | ﹤0.01% | 1935 |
|
|
2019
Q1 | $768K | Buy |
9,588
+7,868
| +457% | +$581K | ﹤0.01% | 1835 |
|
|
2018
Q4 | $92.7K | Sell |
1,720
-2,520
| -59% | -$153K | ﹤0.01% | 2406 |
|
|
2018
Q3 | $331K | Buy |
4,240
+203
| +5% | +$14.1K | ﹤0.01% | 2197 |
|
|
2018
Q2 | $256K | Sell |
4,037
-4,835
| -54% | -$385K | ﹤0.01% | 2329 |
|
|
2018
Q1 | $814K | Buy |
8,872
+111
| +1% | +$9.57K | ﹤0.01% | 1884 |
|
|
2017
Q4 | $661K | Buy |
8,761
+4,629
| +112% | +$326K | ﹤0.01% | 2282 |
|
|
2017
Q3 | $288K | Sell |
4,132
-106
| -3% | -$5.67K | ﹤0.01% | 2273 |
|
|
2017
Q2 | $215K | Buy |
4,238
+4,145
| +4,457% | +$176K | ﹤0.01% | 2411 |
|
|
2017
Q1 | $3.72K | Sell |
93
-1,044
| -92% | -$37.4K | ﹤0.01% | 3376 |
|
|
2016
Q4 | $31.9K | Sell |
1,137
-275
| -19% | -$8.29K | ﹤0.01% | 3018 |
|
|
2016
Q3 | $41.9K | Buy |
1,412
+628
| +80% | +$15.6K | ﹤0.01% | 2509 |
|
|
2016
Q2 | $15.9K | Buy |
+784
| New | +$14.2K | ﹤0.01% | 2689 |
|
|
2016
Q1 | – | Sell |
-1,916
| Closed | -$50.5K | – | 2708 |
|
|
2015
Q4 | $50.5K | Sell |
1,916
-518
| -21% | -$11.7K | ﹤0.01% | 2805 |
|
|
2015
Q3 | $51.9K | Buy |
+2,434
| New | +$67.3K | ﹤0.01% | 2832 |
|
Other funds holding BPMC
IA
HNB
BNP Paribas Financial Markets's BPMC Position: Q3 2025 in Review
BNP Paribas Financial Markets sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 18,556 shares — an estimated $2.38M sold.
BNP Paribas Financial Markets first reported a position in BPMC in Q3 2015 and held it in 39 quarters. The position peaked at $14M in Q4 2023. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- BNP Paribas Financial Markets reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- BNP Paribas Financial Markets sold 18,556 Blueprint Medicines shares in Q3 2025, an estimated $2.38M.
- BNP Paribas Financial Markets first reported a position in Blueprint Medicines in Q3 2015 and held it in 39 quarters.
- BNP Paribas Financial Markets's Blueprint Medicines position peaked at $14M in Q4 2023.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.